文献速递糖尿病

血清腱糖蛋白C与2型糖尿病患者主要不良心血管事件及死亡风险增加独立相关:一项法国前瞻性队列研究

Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort.
PubMed 文献 · Diabetologia · 2020-02-10

研究纳入1321例连续2型糖尿病患者(SURDIAGENE队列),中位随访89个月,442例死亡、497例发生主要不良心血管事件(MACE)。多因素Cox分析显示,血清腱糖蛋白C(TN-C)每增加1个标准差,死亡风险HR为1.27(95%CI 1.17, 1.38;p<0.0001),MACE风险HR为1.23(95%CI 1.13, 1.34;p<0.0001)。在传统危险因素基础上加入TN-C可 modestly 但显著改善死亡(rIDI 8.2%;p=0.0006)和MACE(rIDI 6.7%;p=0.0014)的风险预测。

要点

  • 血清TN-C每升高1个标准差,全因死亡风险HR 1.27(95%CI 1.17, 1.38;p<0.0001)。
  • 血清TN-C每升高1个标准差,MACE风险HR 1.23(95%CI 1.13, 1.34;p<0.0001)。
  • 在传统危险因素上加入TN-C对死亡(rIDI 8.2%;p=0.0006)和MACE(rIDI 6.7%;p=0.0014)预测改善 modestly 但显著。

核心结论

  • 在2型糖尿病患者中,血清TN-C浓度升高与死亡和MACE独立相关。
  • 作者认为,将TN-C作为预后生物标志物可改善这些个体的风险分层。

研究设计与样本

  • 前瞻性、单中心、连续纳入2型糖尿病参与者的SURDIAGENE队列,共1321人(58%为男性,平均年龄64±11岁),中位随访89个月。
  • 主要终点为全因死亡,次要终点为MACE(心血管死亡、非致死性心肌梗死或卒中)。
  • 采用比例风险模型校正传统危险因素,并用相对整合判别改善(rIDI)评估TN-C的增量预测价值。

主要发现

  • 随访期间442人死亡、497人发生MACE。
  • 多因素Cox分析显示,血清TN-C浓度与死亡风险增加相关(每1个标准差HR 1.27,95%CI 1.17, 1.38;p<0.0001)。
  • 多因素Cox分析显示,血清TN-C浓度与MACE风险增加相关(每1个标准差HR 1.23,95%CI 1.13, 1.34;p<0.0001)。
  • 在传统危险因素基础上加入TN-C,全因死亡风险预测改善(rIDI 8.2%;p=0.0006),MACE风险预测改善(rIDI 6.7%;p=0.0014),但幅度 modest。

临床怎么用

  • 作者认为,将TN-C作为预后生物标志物可改善2型糖尿病患者的风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Tenascin-C (TN-C) is an extracellular matrix glycoprotein highly expressed in inflammatory and cardiovascular (CV) diseases. Serum TN-C has not yet been specifically studied in individuals with type 2 diabetes, a condition associated with chronic low-grade inflammation and increased CV disease risk. In this study, we hypothesised that elevated serum TN-C at enrolment in participants with type 2 diabetes would be associated with increased risk of death and major adverse CV events (MACE) during follow-up. METHODS: We used a prospective, monocentric cohort of consecutive type 2 diabetes participants (the SURDIAGENE [SUivi Rénal, DIAbète de type 2 et GENEtique] cohort) with all-cause death as a primary endpoint and MACE (CV death, non-fatal myocardial infarction or stroke) as a secondary endpoint. We used a proportional hazard model after adjustment for traditional risk factors and the relative integrated discrimination improvement (rIDI) to assess the incremental predictive value of TN-C for these risk factors. RESULTS: We monitored 1321 individuals (58% men, mean age 64 ± 11 years) for a median of 89 months. During follow-up, 442 individuals died and 497 had MACE. Multivariate Cox analysis showed that serum TN-C concentrations were associated with an increased risk of death (HR per 1 SD: 1.27 [95% CI 1.17, 1.38]; p < 0.0001) and MACE (HR per 1 SD: 1.23 [95% CI 1.13, 1.34]; p < 0.0001). Using TN-C concentrations on top of traditional risk factors, prediction of the risk of all-cause death (rIDI: 8.2%; p = 0.0006) and MACE (rIDI: 6.7%; p = 0.0014) improved significantly, but modestly. CONCLUSIONS/INTERPRETATION: In individuals with type 2 diabetes, increased serum TN-C concentrations were independently associated with death and MACE. Therefore, including TN-C as a prognostic biomarker could improve risk stratification in these individuals.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Gellen B, Thorin-Trescases N, Thorin E, et al. Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort. Diabetologia. 2020. PMID: 32040670. doi:10.1007/s00125-020-05108-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。